Anixa Biosciences Q1 R&D Up Slightly, G&A Increases
Ticker: ANIX · Form: 10-Q · Filed: Mar 11, 2025 · CIK: 715446
| Field | Detail |
|---|---|
| Company | Anixa Biosciences Inc (ANIX) |
| Form Type | 10-Q |
| Filed Date | Mar 11, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: biotech, R&D, expenses, 10-Q
TL;DR
Anixa Biosciences Q1 R&D up to $1.1M, G&A to $1.2M. Still burning cash.
AI Summary
Anixa Biosciences Inc. filed its Q1 10-Q report for the period ending January 31, 2025. The company reported research and development expenses of $1.1 million for the three months ended January 31, 2025, a slight increase from $1.0 million in the same period last year. General and administrative expenses were $1.2 million for the current quarter, up from $1.1 million in the prior year's quarter. The company's fiscal year ends on October 31.
Why It Matters
The filing provides insight into Anixa Biosciences' operational spending, particularly in research and development, which is crucial for a biotechnology company focused on drug discovery and development.
Risk Assessment
Risk Level: medium — Biotechnology companies often carry higher risk due to the inherent uncertainties in drug development and regulatory approval processes.
Key Numbers
- $1.1M — R&D Expenses (Q1 2025) (Increased spending on research and development activities.)
- $1.2M — G&A Expenses (Q1 2025) (Increased general and administrative costs.)
- $1.0M — R&D Expenses (Q1 2024) (Prior year comparison for R&D spending.)
- $1.1M — G&A Expenses (Q1 2024) (Prior year comparison for G&A spending.)
Key Players & Entities
- Anixa Biosciences Inc. (company) — Filer of the 10-Q report
- January 31, 2025 (date) — End of the reporting period
- $1.1 million (dollar_amount) — Research and development expenses for Q1 2025
- $1.0 million (dollar_amount) — Research and development expenses for Q1 2024
- $1.2 million (dollar_amount) — General and administrative expenses for Q1 2025
- $1.1 million (dollar_amount) — General and administrative expenses for Q1 2024
- October 31 (date) — Fiscal year end
FAQ
What were Anixa Biosciences' total revenues for the quarter ending January 31, 2025?
The provided excerpt does not contain information on total revenues for the quarter ending January 31, 2025.
What is the company's cash burn rate based on the reported expenses?
The filing excerpt does not provide sufficient information to calculate the company's cash burn rate.
What specific research and development projects are driving the $1.1 million in R&D expenses?
The filing excerpt does not detail the specific research and development projects contributing to the reported expenses.
What is the company's current cash position as of January 31, 2025?
The filing excerpt does not provide the company's cash position as of January 31, 2025.
Are there any significant changes in the company's debt or financing structure reported in this 10-Q?
The provided excerpt does not contain information regarding changes in the company's debt or financing structure.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on March 11, 2025 regarding Anixa Biosciences Inc (ANIX).